Invokana (canagliflozin) was approved by the FDA to help patients with type 2 diabetes manage blood sugar levels. However, thousands of people who took this medication have filed lawsuits claiming it caused serious injuries, including limb amputations and kidney failure. Over 1,000 to 1,200 lawsuits have been consolidated into a litigation group in federal court in New Jersey, where patients seek compensation for the harm they suffered. The lawsuits center on two major safety concerns that emerged after the drug hit the market.
Clinical trial data showed that patients taking Invokana were twice as likely to suffer leg or foot amputation compared to those taking placebo. Additionally, the FDA confirmed over 100 cases of acute kidney injury linked to the drug, with approximately half of these occurring within the first month of use. One patient in the litigation reported developing gangrene in his toes after just three months on Invokana, eventually requiring partial amputation of his foot. This litigation is structured as a multidistrict litigation (MDL), not a traditional class action settlement, which means the cases remain individual lawsuits that can be settled separately rather than through one global agreement.
Table of Contents
- What Does the Clinical Evidence Show About Invokana and Amputation Risk?
- How Common Are Kidney Injuries Related to Invokana?
- What Has the FDA Done About Invokana’s Safety Warnings?
- What Compensation Are Plaintiffs Seeking in Invokana Lawsuits?
- What Are the Key Limitations and Challenges in These Lawsuits?
- Who Can File an Invokana Lawsuit?
- What Is the Current Status and Future of Invokana Litigation?
- Conclusion
What Does the Clinical Evidence Show About Invokana and Amputation Risk?
The most alarming evidence against Invokana comes from two large FDA-cited clinical trials called CANVAS and CANVAS-R. These studies tracked patients over several years and compared outcomes between those taking Invokana and those taking a placebo. The results were striking: patients on Invokana were twice as likely to suffer leg or foot amputation. This wasn’t a minor statistical difference—it represented a doubling of the amputation risk, which alarmed both researchers and the FDA.
The CANVAS studies included thousands of patients with type 2 diabetes, making the findings hard to dismiss as outliers. After reviewing this data, the FDA took the unusual step in 2017 of adding a black box warning—the strongest warning label available—specifically for the increased risk of amputation. This warning alerted doctors and patients that Invokana carried a serious danger beyond the typical side effects of diabetes medications. The key limitation to understand is that not every patient on Invokana will suffer amputation; the risk increase is relative, not absolute, yet for those who did experience this complication, the consequences were life-altering.
How Common Are Kidney Injuries Related to Invokana?
Kidney damage emerged as another critical safety issue with Invokana. Between March 2013 and October 2015, the FDA confirmed 101 reports of acute kidney injuries in patients taking the drug. What made this particularly concerning was the timing: approximately half of these kidney damage cases showed signs of injury within the first month of starting the medication. This rapid onset suggested that the drug’s effects on kidney function happened quickly in vulnerable patients, leaving little time for doctors to monitor and intervene before serious damage occurred.
The mechanism of kidney injury isn’t fully understood, but the drug appears to affect how the kidneys filter and regulate fluids and electrolytes. Some patients experienced a sharp decline in kidney function that required hospitalization and dialysis. The FDA’s own investigation found that many patients recovered some kidney function after stopping the drug, but others experienced permanent damage. A limitation worth noting is that patients with pre-existing kidney disease are at higher risk, yet some patients without prior kidney problems still developed acute kidney injuries, suggesting Invokana can harm kidneys even in those without established disease.
What Has the FDA Done About Invokana’s Safety Warnings?
The FDA’s response to Invokana safety concerns evolved over time as new evidence accumulated. In 2017, the agency added the black box warning for increased amputation risk, reflecting the serious nature of the CANVAS trial findings. This warning represented a major acknowledgment that Invokana posed dangers beyond what was initially disclosed when the drug was approved in 2013. Doctors were required to inform patients, and prescribing patterns began to shift as physicians became more cautious.
However, the FDA’s stance changed in late 2020 when the agency removed the black box warning for amputation risk based on what regulators described as new data showing the amputation risk was lower than previously reported. This decision generated significant debate within the medical and legal communities, with some arguing the new data was incomplete. The amputation risk remains listed in the “Warnings and Precautions” section of Invokana’s label, meaning it hasn’t been completely dismissed—just downgraded from the highest alert level. For plaintiffs in ongoing litigation, the FDA’s decision to remove the black box warning has complicated their arguments, though the lawsuits continue because patients argue they were harmed based on the earlier safety profile and lack of adequate warnings at the time they took the drug.
What Compensation Are Plaintiffs Seeking in Invokana Lawsuits?
Plaintiffs in the Invokana litigation seek compensation that reflects the severity of their injuries. Depending on the type and extent of harm, damage amounts typically range from $25,000 to over $1,000,000 per case. Someone who suffered a minor kidney injury and recovered might seek lower compensation, while a patient who required amputation or suffered permanent kidney failure would pursue much higher damages. The variation reflects the reality that injuries have different impacts on people’s lives and medical costs.
However, it’s important to understand that no global settlement agreement has been reached between the plaintiffs and Janssen Pharmaceuticals (the manufacturer) or its parent company, johnson & Johnson. Instead, individual settlements have occurred on a case-by-case basis, and the amounts of these settlements remain confidential—meaning injured patients often don’t know what others received for similar injuries. The lack of a comprehensive settlement agreement means the litigation continues, with hundreds of cases still pending in the MDL as of the most recent reports. This drawn-out process can take years, during which injured plaintiffs must wait for compensation while managing ongoing medical costs and disabilities.
What Are the Key Limitations and Challenges in These Lawsuits?
One significant challenge in Invokana litigation is proving that the drug caused a specific injury, rather than the patient’s underlying diabetes or other medical conditions. Defendants argue that type 2 diabetes itself increases amputation and kidney disease risk, so proving Invokana specifically caused the harm requires careful medical documentation and expert testimony. Patients who had multiple risk factors for kidney disease or amputation may have more difficulty establishing causation than those without complicating conditions. This means some injured people may struggle to win their cases despite having suffered genuine harm.
Another limitation is the role of the FDA’s decision to remove the black box warning. While the FDA has not eliminated amputation risk from the warning label entirely, the removal of the black box designation can be cited by defendants as evidence that the risk was overstated. Plaintiffs argue that the warnings at the time the drug was prescribed are what matters legally, not subsequent regulatory changes. Additionally, patients who continued taking Invokana after the 2017 black box warning was added may face arguments that they voluntarily assumed the known risk, which could reduce their damages even if they can prove the drug caused their injury.
Who Can File an Invokana Lawsuit?
Patients who took Invokana and subsequently suffered leg or foot amputation, acute kidney injury, or chronic kidney failure may be eligible to file a claim in the MDL. You don’t need to have filed suit already; you can bring your case as part of the existing litigation, and attorneys handling Invokana cases typically work on contingency, meaning they collect fees only if you win or settle.
The key requirement is that you have medical records documenting that you took Invokana and that you developed one of the serious injuries linked to the drug. For example, a patient who took Invokana for 18 months and then developed kidney failure requiring dialysis would have a strong foundation for a claim, especially with hospital records showing the kidney damage occurred shortly after starting the medication.
What Is the Current Status and Future of Invokana Litigation?
As of December 2017, more than 990 cases were pending in the Invokana MDL, though the total number has fluctuated as some cases settle and new ones are filed. The litigation has persisted for years without a global resolution, suggesting that either the defendants and plaintiffs’ attorneys have significant disagreements about liability and damages, or the complexity of individual cases makes a mass settlement difficult to negotiate. Unlike some major product liability cases that result in a single settlement fund available to all claimants, Invokana plaintiffs largely navigate their own settlement discussions through their attorneys.
Looking forward, the litigation may eventually resolve through a combination of individual settlements, jury verdicts, and possible appellate decisions. The FDA’s removal of the black box warning may reduce the number of new cases but could also complicate settlements for those already injured. Patients considering filing a claim should act promptly, as statutes of limitations (the deadlines to sue) apply, and evidence may become harder to gather as time passes. The landscape of Invokana litigation remains unsettled, which means plaintiffs and their families must stay informed about developments in the MDL to understand how changes may affect their cases.
Conclusion
The Invokana litigation represents one of the significant drug injury cases in recent years, with over 1,000 lawsuits filed against the manufacturer for causing amputations and kidney failure. The clinical evidence showing that patients on Invokana were twice as likely to suffer amputation, combined with over 100 FDA-confirmed cases of acute kidney injury, formed the foundation for these claims. While the FDA added a black box warning in 2017 and later removed it in 2020, the underlying injuries to patients have not changed, and their right to seek compensation through litigation remains intact.
If you or a family member took Invokana and suffered amputation, kidney injury, or kidney failure, you may be eligible to join the MDL and pursue compensation. Contact an attorney experienced in drug litigation to discuss your case, medical records, and potential damages. The litigation is ongoing, and while no global settlement exists, individual cases continue to resolve. Understanding where the litigation stands and what evidence supports your claim will help you make informed decisions about pursuing justice and compensation.